Effect of Denosumab and Alendronate on glucocorticoid-induced osteoporosis in patients with glomerulonephritis:a randomized controlled trial
Phase of Trial: Phase II
Latest Information Update: 02 May 2017
At a glance
- Drugs Denosumab (Primary) ; Alendronic acid
- Indications Corticosteroid-induced osteoporosis
- Focus Therapeutic Use
- 28 Apr 2017 Status changed from active, no longer recruiting to completed.
- 01 Jul 2016 Status changed from recruiting to active, no longer recruiting.
- 06 Nov 2015 New trial record